PO.TB04.06 · 肿瘤生物学
In Vivo Models 1: Mouse, Zebrafish, and Alternative Species
-
-
-
-
-
-
-
-
-
- 2163 2163 Triple-negative breast cancer PDX models with acquired resistance to Enhertu ® : A preclinical platform to uncover mechanisms of escape Emilie INDERSIE, Benjamin GUERRIN, Eugenie DELHORBE, Eva CYPRIEN, Elena DARBINEAN, Delphine NICOLLE, Marie TAVERNIER, Olivier DÉAS
- 2164 2164 Breast cancer PDX models with acquired resistance to olaparib: A preclinical platform to uncover mechanisms of PARP inhibitor escape Emilie INDERSIE, Benjamin GUERRIN, Eugenie DELHORBE, Eva CYPRIEN, Elena DARBINEAN, Delphine NICOLLE, Marie TAVERNIER, Olivier DÉAS
-
-
-
-
- 2170 2170 Patient-derived orthotopic xenograft models predict chemotherapeutic response in pancreatic ductal adenocarcinoma: an emerging platform for translational research Xin Zhang, Nathan Bolton, Alicia Ray, Grace Maresh, Rachel Graham, Li Li
-
-
- 2173 2173 Development of novel syngeneic mouse models of mHSPC and mCRPC for evaluation of radiopharmaceuticals on the immune tumor microenvironment (TME) Brian Ragaishis, Andrei Molotkov, Shruti Bansal, Krishan Saini, Maierdan Palihati, Chelsea Rahiman, Courtney Buress, Jasleen Kaur Virk, Mikhail Doubrovin, Catherine Spina
- 2174 2174 A comprehensive CRISPR/Cas9-based RAS knock-in cell line platform (50+ models) for assessing efficacy of KRAS-targeted inhibitors in RAS-mutant malignancies. Lin Zhou, Guoqian Wang, Tingduo Lv, Zidan Su, Yue Huang, Jinying Ning, Feng Hao
-
- 2177 2177 Characterization of a panel of PDX models derived from PARP inhibitors pretreated breast and ovarian cancer patients for therapeutic evaluation Qingzhi Liu, Jinxi Wang, Leilei Chen, Wubin Qian, Likun Zhang, Ludovic Bourre, Jessie Jingjing Wang
-
-
